Apollomics Stock Set to Reverse Split on Monday, November 25th (NASDAQ:APLM)

Apollomics, Inc. (NASDAQ:APLM) shares are scheduled to reverse split on Monday, November 25th. The 1-100 reverse split was announced on Thursday, November 21st. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, November 22nd.

Apollomics Trading Down 32.6 %

APLM stock traded down $0.05 during trading on Thursday, reaching $0.10. The company’s stock had a trading volume of 11,199,390 shares, compared to its average volume of 9,109,365. The company’s fifty day moving average is $0.13 and its 200-day moving average is $0.18. Apollomics has a 1 year low of $0.08 and a 1 year high of $1.23.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Apollomics stock. George Kaiser Family Foundation grew its position in shares of Apollomics, Inc. (NASDAQ:APLM) by 2,585.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 670,976 shares of the company’s stock after purchasing an additional 645,992 shares during the period. Apollomics makes up approximately 0.0% of George Kaiser Family Foundation’s investment portfolio, making the stock its 18th biggest position. George Kaiser Family Foundation owned 0.75% of Apollomics worth $141,000 at the end of the most recent reporting period. 19.13% of the stock is currently owned by hedge funds and other institutional investors.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.